| Literature DB >> 34409334 |
Minghui Wei1,2, Cheng Xie2,3, Yubo Liu4, Yuhong Wang1,2, Yuanyuan Wang1,2, Xinwen Wang1,2, Yuan Liu2,5.
Abstract
BACKGROUND: Racial variation exists in the incidence of orofacial granulomatosis (OFG). The epidemiology and clinical characteristics of OFG in Asian countries are poorly described.Entities:
Keywords: CI, confidence interval; OFG, orofacial granulomatosis; dental treatment; granulomatous cheilitis; long-term outcome; odontogenic infection; orofacial granulomatosis; periapical infection
Year: 2020 PMID: 34409334 PMCID: PMC8362245 DOI: 10.1016/j.jdin.2020.07.003
Source DB: PubMed Journal: JAAD Int ISSN: 2666-3287
The spectrum of OFG
| Intra-oral manifestations |
| Cobblestoning |
| Gingival enlargement |
| Mucosal tags |
| Fissured tongue |
| Extra-oral manifestations |
| Lip swelling |
| Perioral swelling or erythema |
| Facial swelling |
| Angular cheilitis |
Fig 1Flowchart of the orofacial granulomatosis patients being followed. One hundred twenty-eight patients were eligible for the treatment analysis (after exclusion, 1 died patient, 24 received combined therapy, 5 were unwilling or unable to attend, and 7 were noncontactable), 59 of 128 patients received intralesional corticosteroid injection, 11 of 128 patients who refused management with intralesional corticosteroid injection received thalidomide, and 58 of 128 with odontogenic infection consented to receive dental treatment as first-line treatment. DT, Dental treatment; ITD, intralesional compound betamethasone therapy; OFG, orofacial granulomatosis; OFG-I, orofacial granulomatosis infected; OFG-N, orofacial granulomatosis negative; TM, thalidomide therapy.
Baseline characteristics and medical history for orofacial granulomatosis patients according to odontogenic infection
| Variable | Total (n = 165) | OFG-N (n = 47) | OFG-I (n = 118) | |
|---|---|---|---|---|
| Age at disease onset, y | 49 (5-83) | 39 (5-72) | 51 (20-83) | <.001 |
| Age, y | 51 (5-83) | 41 (5-72) | 53 (23-83) | <.001 |
| Women | 52 (7-83) | 49 (7-72) | 53 (23-83) | |
| Men | 45 (5-77) | 30 (5-63) | 53 (32-77) | |
| Women, No. (%) | 117 (70.9) | 23 (48.9) | 94 (79.7) | <.001 |
| Duration of disease, mo | 12 (1-240) | 10 (2-120) | 12 (1-240) | .32 |
| Medical history, No. (%) | ||||
| Allergy | 32 (19.4) | 9 (19.1) | 23 (19.5) | >.99 |
| Cardiovascular diseases | 45 (27.3) | 8 (17.0) | 37 (31.4) | .04 |
| Digestive system diseases | 15 (9.1) | 4 (8.5) | 11 (9.3) | >.99 |
| Skin diseases | 4 (2.4) | 1 (2.1) | 3 (2.5) | >.99 |
| Endocrine diseases | 3 (1.8) | 1 (2.1) | 2 (1.7) | >.99 |
| Urinary system diseases | 3 (1.8) | 0 | 3 (2.5) | |
| Nervous system disease | 3 (1.8) | 0 | 3 (2.5) | |
| Respiratory disease | 2 (1.2) | 1 (2.1) | 1 (0.8) | .49 |
| Autoimmune diseases | 2 (1.2) | 1 (2.1) | 1 (0.8) | .49 |
| Genital system diseases | 2 (1.2) | 0 | 2 (1.7) | |
| Clinical characteristics of OFG | ||||
| Lip enlargement, No. (%) | .25 | |||
| Upper lip | 44 (26.7) | 15 (31.9) | 29 (24.6) | |
| Lower lip | 73 (44.2) | 16 (34.0) | 57 (48.3) | |
| Both lips | 48 (29.1) | 16 (34.0) | 32 (27.1) | |
| Extent of disease, No. (%) | ||||
| Solely lip manifestation | 57 (34.5) | 33 (70.2) | 24 (20.3) | <.001 |
| Intraoral manifestation | 30 (18.2) | 7 (14.9) | 23 (19.5) | .66 |
| Perioral or facial swelling, erythema | 78 (47.3) | 7 (14.9) | 71 (60.2) | <.001 |
Data are expressed as median (range) unless otherwise indicated.
OFG, Orofacial granulomatosis; OFG-I, orofacial granulomatosis infected; OFG-N, orofacial granulomatosis negative.
Indicates which group has been compared between women and men and that the difference is statistically significant.
Fig 2Age distribution at disease onset between the 165 male and female orofacial granulomatosis patients. The peak incidence was in the fifth and sixth decades.
Demographic and clinical characteristics of compound betamethasone–treated patients according to response to treatment
| Variable | No response (n = 9) | Relapse (n = 40) | Remission (n = 10) | |
|---|---|---|---|---|
| Age, y | 45 ± 21 | 45 ± 15 | 47 ± 11 | .93 |
| Women, No. (%) | 6 (66.7) | 21 (52.5) | 7 (70.0) | .53 |
| Duration of disease, mo | 22 ± 17 | 19 ± 23 | 25 ± 35 | .78 |
| Total follow-up, mo | 30 ± 25 | 40 ± 28 | 28 ± 22 | .35 |
| Odontogenic infection, No. (%) | 6 (66.7) | 20 (50.0) | 3 (30.0) | .30 |
| Lip enlargement, No. (%) | .65 | |||
| Upper | 2 (22.2) | 11 (27.5) | 3 (30.0) | |
| Lower | 5 (55.6) | 12 (30.0) | 4 (40.0) | |
| Both | 2 (22.2) | 17 (42.5) | 3 (30.0) | |
| Extent of disease, No. (%) | .39 | |||
| Solely lip manifestation | 3 (33.3) | 17 (42.5) | 6 (60.0) | |
| Intraoral manifestation | 5 (55.6) | 16 (40.0) | 2 (20.0) | |
| Perioral or facial swelling, erythema | 1 (11.1) | 7 (17.5) | 2 (20.0) |
Data are expressed as mean ± standard deviation. Remission group included partial remission and complete remission cases.
Demographic and clinical characteristics and treatment outcome of the orofacial granulomatosis patients with odontogenic infection and receiving different treatments
| Variable | Compound betamethasone (n = 29) | Dental treatment (n = 58) | Thalidomide (n = 5) | |
|---|---|---|---|---|
| Age, y | 53 ± 9 | 51 ± 11 | 60 ± 6 | .1 |
| Women, No. (%) | 22 (75.9) | 46 (79.3) | 4 (80.0) | .9 |
| Duration of disease, mo | 18 ± 22 | 26 ± 43 | 41 ± 33 | .4 |
| Total follow-up, mo | 39 ± 29 | 35 ± 21 | 29 ± 28 | .6 |
| Lip enlargement, No. (%) | .9 | |||
| Upper | 8 (27.6) | 15 (25.9) | 1 (20.0) | |
| Lower | 13 (44.8) | 29 (50.0) | 2 (40.0) | |
| Both | 8 (27.6) | 14 (24.1) | 2 (40.0) | |
| Extent of disease, No. (%) | .8 | |||
| Solely lip manifestation | 5 (17.2) | 13 (22.4) | 2 (40.0) | |
| Intraoral manifestation | 18 (62.1) | 29 (50.0) | 2 (40.0) | |
| Perioral or facial swelling, erythema | 6 (20.7) | 16 (27.6) | 1 (20.0) | |
| Response to treatment | <.001 | |||
| No response | 6 (20.7) | 1 (1.7) | 2 (40.0) | |
| Relapse | 20 (69.0) | 0 | 1 (20.0) | |
| Partial remission | 2 (6.9) | 26 (44.8) | 2 (40.0) | |
| Complete remission | 1 (3.4) | 31 (53.4) | 0 | |
Data are expressed as mean ± standard deviation.